In the intent-to-treat population, the median progression-free survival (PFS) was 8.77 months with giredestrant plus Afinitor ...

Verzenio plus endocrine therapy reduced death risk by 15.8% in high-risk early breast cancer patients compared to endocrine ...

Medically reviewed by Lindsay Cook, PharmD Key Takeaways HER2-positive breast cancers have more HER2 receptors and can grow and spread faster than HER2-negative cancers.HER2 status should be tested ...

Gedatolisib combined with fulvestrant, with or without palbociclib, significantly improved PFS in HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer. The triplet regimen reduced ...

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer Seven-year results from the ...

Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed ...

In breast cancer patients with a high recurrence score, the 5-year disease-free rate was significantly higher for patients receiving taxanes with anthracycline and cyclophosphamide than for those ...

These Phase III results could enhance uptake of Eli Lilly's Verzenio alongside ET in the adjuvant breast cancer setting, if ...

Breast cancer is a complex disease with many types. Understanding the specific type and classification of the breast cancer you have is crucial so that you can fully participate as an informed partner ...

A research trial spearheaded by Merck hopes to change that — and Franciscan Health Indianapolis is at the forefront too, as it is the only hospital in Indiana selected to take part in the ...